Acasti Pharma, Inc.
Acasti Pharma develops pharmaceutical products for rare diseases in Canada. Its lead product is GTX-104, an IV infusion to treat subarachnoid hemorrhage. It also works on GTX-102, a spray for ataxia-telangiectasia, and GTX-101, a topical spray for postherpetic neuralgia. The company was founded in 2002 and is based in New Jersey.
Overview
Strengths
- Price to book ratio (0.56) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (3.24) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 3.2 |